Participants received anthracycline-based neoadjuvant chemotherapy (cyclophosphamide of 500 mg/m2, doxorubicin of 50 mg/m2 and fluorouracil/5FU of 500 mg/m2) for 3 cycles….Based on cutoff 1, most participants with high TNF-α levels also had a negative response of 83.3% and those with low TNF-α levels also had a positive response of 75% (P<0.001)....TNF-α levels predict clinical response for anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer patients.